Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome

Immune response to therapeutic enzymes poses a detriment to patient safety and treatment outcome. Enzyme replacement therapy (ERT) is a standard therapeutic option for some types of mucopolysaccharidoses, including Morquio A syndrome caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) defici...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Sosa, Angela C., Kariuki, Barbara, Gan, Qi, Knutsen, Alan P., Bellone, Clifford J., Guzmán, Miguel A., Barrera, Luis A., Tomatsu, Shunji, Chauhan, Anil K., Armbrecht, Eric, Montaño, Adriana M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269574/
https://ncbi.nlm.nih.gov/pubmed/31743109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI125607
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars